{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:07:49Z","timestamp":1789708069093,"version":"4.0.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD), asthma, and eosinophilic esophagitis (EoE) may coexist because they share type 2 inflammatory pathways. Evidence for dupilumab in children with EoE and other gastrointestinal manifestations remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 7-year-old girl had poorly controlled AD, recurrent asthma, EoE (&amp;gt;100 eosinophils\/high-power field), and lower-density eosinophilic infiltration in gastric, ileal, and colonic biopsies. These extraesophageal findings did not uniformly satisfy proposed thresholds for definite non-EoE eosinophilic gastrointestinal disease. Severe AD despite topical therapy was the primary indication for dupilumab; the coexisting type 2 inflammatory disorders supported selection of a pathway-directed systemic treatment. Dupilumab was administered as a 600-mg loading dose followed by 300\u2005mg subcutaneously every 4 weeks. Over 48 weeks, pruritus resolved, skin lesions markedly improved, wheezing did not recur, inhaled salmeterol\/fluticasone was reduced, appetite improved, and vomiting ceased. Follow-up endoscopy showed a smooth esophagus and no obvious duodenal abnormality, although gastric inflammation and small ulcers persisted and repeat histology was unavailable. Total IgE decreased from &amp;gt;2,000 to 211.2 IU\/mL; peripheral eosinophils decreased from 0.64 to 0.30\u2009\u00d7\u200910\u2079\/L. No treatment-related adverse events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that IL-4\/IL-13 blockade may provide coordinated clinical benefit across multiple type 2 inflammatory organs. The gastrointestinal findings should be interpreted cautiously because symptom improvement was not confirmed by repeat biopsy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1929466","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:31:26Z","timestamp":1789705886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Multisystem response to dupilumab in a child with atopic dermatitis, asthma, eosinophilic esophagitis, and other gastrointestinal manifestations"],"prefix":"10.3389","volume":"7","author":[{"given":"Hua-Jie","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Nanxiang Hospital of Jiading District","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nanxiang Hospital of Jiading District","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Nan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nanxiang Hospital of Jiading District","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yun","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nanxiang Hospital of Jiading District","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaci.2018.11.006","article-title":"The atopic march and atopic multimorbidity: many trajectories, many pathways","volume":"143","author":"Paller","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"984","DOI":"10.14309\/ajg.0000000000000228","article-title":"Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis","volume":"114","author":"Pesek","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jaci.2024.03.013","article-title":"Common and disparate clinical presentations and mechanisms in different eosinophilic gastrointestinal diseases","volume":"153","author":"Shoda","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/MPG.0000000000003829","article-title":"ESPGHAN\/NASPGHAN guidelines on childhood eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis","volume":"78","author":"Papadopoulou","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1111\/all.15432","article-title":"Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis","volume":"77","author":"Berdyshev","year":"2022","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","article-title":"Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomized, double-blind, placebo-controlled, phase 4 trial","volume":"13","author":"Castro","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5414\/ALX02485E","article-title":"Rapid response to dupilumab in an adult patient with eosinophilic esophagitis and allergic asthma","volume":"8","author":"Klein","year":"2024","journal-title":"Allergol Select"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e00646","DOI":"10.14309\/ctg.0000000000000646","article-title":"Dupilumab can induce remission of eosinophilic gastritis and duodenitis: a retrospective case series","volume":"15","author":"Sia","year":"2024","journal-title":"Clin Transl Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13223-023-00859-3","article-title":"Successful use of dupilumab for egg-induced eosinophilic gastroenteritis with duodenal ulcer: a pediatric case report and review of literature","volume":"19","author":"Tsuge","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/MPG.0000000000003512","article-title":"A case series on the use of dupilumab for treatment of refractory eosinophilic gastrointestinal disorders","volume":"75","author":"Patel","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1929466\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:31:51Z","timestamp":1789705911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1929466\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":12,"alternative-id":["10.3389\/falgy.2026.1929466"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1929466","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1929466"}}